Today’s AI Top Pick: SPRO

7/29/2026 · Contrarian screen · a free sample of K3vl4r’s AI-curated picks.

AI-ranked from a screened shortlist, with entry strategy, targets, and risks.

Today's pick · ContrarianSPROBUY NOW8.6 / 107/29/2026

SPRO is the standout buy today because it combines the pool's strongest fundamentals (fundamental_score 8, PE 4.9, fwdPe 1.78, ROE 35.12%, profit margin 27.82%, debt/equity 0.05) with a concrete, real-money positive catalyst that just dropped: on Jul 15 Innovent licensed IBI355 rights to Spero in a deal worth up to $1.1B, and Spero also announced China cut deals — that's a material fundamental change on a $69M market cap company. Meanwhile the tape is deeply washed out (RSI 21.78, drawdown -45.7% on the daily, price sitting at the 3.77 percentile of the 21-bar range, -45.95% from the 21-bar high), which is exactly the exhausted-selling setup this lens is designed to catch. Multi-timeframe forecasts back the bounce hard: 1h fc_short +110.29% / fc_mid +123.56% / fc_long +149.96%, 4h fc_short +120.20% / fc_mid +101.15% / fc_long +95.06%, 1d fc_short +7.80% / fc_mid +105.79% / fc_long +80.37%. Bullish_prob is 1.0 and near_term_bullish is 0.6. The one blemish is the 1wk forecast rolling over (-28.59 / -17.40 / -16.90), but that is a lower-frequency lag effect from the vertical drop; the shorter timeframes and the new licensing revenue narrative dominate for a swing-trade horizon. Why today, not later: the 1h position_in_21bar_range is 61.54% — mid-range, not chasing an extension — and the 4h/1d are still pinned near the lows (1.02% and 3.77%), meaning you're buying before the higher timeframes lift off. Analyst targetUpsidePct is +233.3% and epsNextY estimate is +331%. Combine washed-out price, an actual catalyst, cheap valuation, and strong short-horizon Kronos forecasts and you have the cleanest asymmetric bet in the pool. I passed on otherwise interesting names because of headline risk: REPL crashed 32% on Jul 28 after FDA reviewers flagged efficacy concerns on RP1 ahead of the AdCom this week — a broken setup, not a dip. EVH was downgraded by Citi on Jul 23 and 'stock is nosediving' — the forecast is undercut by a real analyst action. BESS is the closest runner-up (fresh $6.4M cash catalyst, fund score 6, fwdPe 2.39) but is already at the 94th percentile of its 1h range, so the entry is worse than SPRO's.

Entry zone

$1.15–$1.25 (scale in around current $1.20; add on any tag of $1.10)

Stop loss

$0.95 daily close (below the -45.95% dd_from_21bar_high floor; ~20% risk)

First target

$1.65 (retrace toward mid of 21-bar 4h range; ~+37%)

Longer target

$2.40–$2.60 (aligns with 1d fc_mid +105% and analyst upside; ~+100–115%)

Risks

1wk Kronos forecasts are negative (-28.6% / -17.4% / -16.9%), so the higher timeframe still hasn't confirmed — a failed bounce could resume the -48.71% YTD downtrend
Analyst recom of 3.0 (Hold) means sell-side is not endorsing the story yet despite the Innovent deal — a follow-on offering to fund the milestone payments would dilute a $69M market cap fast
Micro-cap liquidity ($69M market cap, $1.20 stock): expect slippage and gap risk; short_float only 4.94% so no squeeze fuel
The Innovent/China deal headline was Jul 15 — two weeks old — so some of the catalyst is already discounted; if no follow-through PR emerges, momentum can fade
Biotech binary risk on partnered pipeline; a negative trial/regulatory update on IBI355 or Spero's own programs would invalidate the thesis

Honorable mentions

BESSFund score 6, fwdPe 2.39, fresh $6.4M cash receipt announced Jul 28, and 4h/1d forecasts of +41.7/+74.4/+102.9 and +5.1/+57.5/+90.5 with bullish_prob 1.0. Held back only because 1h position_in_21bar_range is 94.29% — you're buying near a local high, so wait for a pullback to ~$2.85.

NAUTQ2 earnings just printed with 'strategic shifts,' RSI 23.53, dd -35.83% on 1d and 0% position_in_range on both 4h and 1d (bottomed), with strong 4h forecasts (+97.9/+100.4/+100.7) and 1d fc_long +59.98%. Weaker fundamentals (score 1.5) and no clear positive catalyst keep it below SPRO.

Full ranking (30)

#	Symbol	Verdict	Score	Read
1	SPRO	BUY NOW	8.6	Oversold (RSI 21.78) with $1.1B Innovent licensing catalyst, cheapest valuation in the pool (fwdPe 1.78), and multi-timeframe forecasts of +105–150% into mid horizon.
2	BESS	BUY PULLBACK	7.4	Strong fund score 6 and a real $6.4M cash catalyst, but 1h at 94th percentile of range — wait for a dip.
3	NAUT	BUY NOW	7.0	Fully washed (0% range position on 4h and 1d) with post-earnings strategic pivot and 4h forecasts near +100%.
4	ADTN	BUY NOW	6.7	Analyst Buys reiterated (B. Riley, Needham) despite PT cuts, fund score 5.75, 1h fc +79% with price at 0% of 1d range.
5	SST	BUY PULLBACK	6.4	Massive 1d/1wk forecasts (+159 / +323 long) and dd -34.5%, but micro-float and weak fundamentals warrant a lower entry.
6	TGEN	BUY PULLBACK	6.2	Fresh $3.3M order + $8M backlog news, dd -42%, but 1wk forecasts turning negative (-45% long).
7	AKTX	BUY PULLBACK	5.9	Maxim upgrade to Buy $30 PT and 1d fc +123%, but 1h and 1wk models both point down — mixed timeframe agreement.
8	LODE	BUY PULLBACK	5.8	Q2 earnings showed strong cash, dd -31.7%, but 1wk forecasts flat/negative and fund score only 2.
9	CRML	BUY PULLBACK	5.6	Fresh lows and forecasts +90–100% on 4h, but 'worst month in over a year' narrative and 'overvalued' Simply Wall St flag.
10	TEM	BUY PULLBACK	5.4	Cathie Wood added $8.7M and Q2 beat expected, but 1h at 92nd percentile — chasing risk into earnings.
11	RUN	BUY PULLBACK	5.3	PE 4.5, ROE 19.1, 1d fc +51.7 mid, but 28.65% short float and negative epsNextY guidance -61.62.
12	NEAR-USD	BUY PULLBACK	5.1	1wk fc_long +72.9% and near_term_bullish 1.0, but sitting on 200-day support — needs to hold $1.52.
13	INV	WAIT	4.9	Huge 1wk forecast (+299% long) but PS 76 and profit margin -5226% make it pure speculation.
14	SKIN	BUY PULLBACK	4.8	Zacks upgrade to Strong Buy and FDA clearance, but debt/equity 6.65 and weak fund score -1.75.
15	METC	WAIT	4.7	4h fc +77 and 1d fc +52/+67, but Goldman cut PT to $13 and negative Q2 earnings warning.
16	NXL	WAIT	4.6	1d fc +86% long but $7M market cap, ROE -320%, no meaningful news catalyst.
17	YCBD	WAIT	4.5	1wk fc shows a 933% outlier — model artifact, not signal — micro-cap $5M with soft news.
18	SKL-USD	WAIT	4.4	1d fc_long +165% but 1wk fc collapses -71.5%; no near-term catalyst.
19	XCH	BUY PULLBACK	4.3	1d fc +138% long from a total washout, but only $27M cap, no analyst coverage, profit margin -129%.
20	TIA-USD	WAIT	4.2	Weakest crypto setup: near_term_bullish 0.2 and ecosystem 'begins to crumble' per prior coverage.
21	PMEC	WAIT	4.1	Deep dd -34% and 1d fc +134% long, but 1wk fc negative and no institutional interest (0.08% instOwn).
22	HOPR-USD	WAIT	4.0	1wk fc +49–78% but daily forecasts flat/slightly negative; not the best crypto here.
23	GXAI	WAIT	3.8	RSI 20.81 and post-divestiture pivot narrative, but stock actively sliding on the news day itself.
24	AIIO	AVOID	3.5	Fund score -3.25, sales -92%, and 1h fc -88% blows a hole in the multi-timeframe agreement.
25	BGDE	AVOID	3.3	Just filed a resale prospectus for 10.9M shares (dilution overhang) and ROE -1568%.
26	ACDC	WAIT	3.2	Fund score -0.75, sell-side recom 3.75, and 'shares are falling' narrative undercuts forecast.
27	RPD	AVOID	3.0	Target upside is NEGATIVE -16.2%, Morgan Stanley cautious on cyber valuations, 1h/4h forecasts negative on mid/long.
28	LNAI	AVOID	2.6	PS 507.77, profit margin -612,568%, and 1wk fc_long is -100% — broken microcap.
29	EVH	AVOID	2.4	Citigroup downgrade on Jul 23 and 'stock is nosediving' headline — thesis materially undercut.
30	REPL	AVOID	1.8	FDA staff raised efficacy concerns on RP1 ahead of AdCom this week; stock crashed 32% on Jul 28 — falling knife into a binary event.

Get AI top picks & forecasts on any stock

K3vl4r screens the market daily and ranks the best setups with AI — forecasts, scored fundamentals & technicals, and multi-horizon price targets. Create a free account to explore them all.

Create your free account →

Already a member? Sign in · Join our Discord